Adverse Events and Recalls

Falsified Ozempic Batches Trigger WHO Warning

June 25, 2024

This alert follows a similar one from the European Medicines Agency in October 2023 amid a rise in demand for the diabetes medication that, in turn, created a shortage.

EMA Reviews Risks Associated with Painkillers and CAR T-Cell Medicines

June 18, 2024

The agency is evaluating risks associated with the painkiller metamizole. It is also reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.

FDA’s Drug Safety Priorities for 2023

February 21, 2024

FDA's Drug Safety Priorities FY23 describes the center’s key safety programs and activities involved in promoting and protecting public health.

EMA Starts Safety Review of CAR T-Cell Medicines

January 17, 2024

The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.

Precautionary Measures Recommended in Use of Valproate Medicines

January 15, 2024

The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.

Voluntary Nationwide Recall of Brimonidine Tartrate Ophthalmic Solution, 0.15%

March 06, 2023

Any patients who have received the identified lots or have any questions regarding the recall should contact their pharmacy or immediately contact a health provider in terms of medical advice.

Spectrum Laboratory Products Issues Recall of Epinephrine USP Bulk API Due to Discoloration

January 11, 2023

Epinephrine is a critical medication used during life-threatening conditions that can affect any age and any person.

Pfizer Issues Voluntary Nationwide Recall of Lots of Accupril

April 25, 2022

Pfizer has issued a voluntary nationwide recall of lots of Accupril due to N-nitroso-quinapril content.

Mylan Pharmaceuticals Issues Voluntary Recall of Insulin Glargine Injection

April 15, 2022

Mylan Pharmaceuticals is issuing a voluntary recall of one batch of insulin glargine injection due to the potential for a missing label in the batch.

Teva Issues Voluntary Nationwide Recall of IDArubicin Hydrochloride Injection USP 5 mg/5 mL

April 08, 2022

Teva has initiated a voluntary nationwide recall of one lot of IDArubicin Hydrochloride Injection USP 5mg/5 mL due to the presence of particulate matter.